All In Biotech

Drug Trial Radar · NCT04801420

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 625 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

625

Actual

Start

Mar 8, 2021

Primary completion

Mar 25, 2022

Study completion Jul 2, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Valneva Austria GmbH
First posted
Mar 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.

Conditions

  • Lyme Borreliosis

Interventions

  • VLA15Biological

    a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

  • PlaceboBiological

    PBS (Phosphate Buffered Saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1Time frame: From Day 1 to Day 7 after vaccination 1 at Month 0
  2. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2Time frame: From Day 1 to Day 7 after vaccination 2 at Month 2
  3. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3Time frame: From Day 1 to Day 7 after vaccination 3 at Month 6
  4. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study PhaseTime frame: From Day 1 to Day 7 after any vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively
  5. Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study PhaseTime frame: At Day 208 (Month 7)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • New England Research Associates

    Bridgeport, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Pediatric Associates of Conn. PC

    Waterbury, Connecticut

  • Clinical Research Institute, Inc.

    Minneapolis, Minnesota

  • Foundation Pediatrics

    East Orange, New Jersey

  • Med Clinical Research Partners, LLC

    Irvington, New Jersey

  • Meridian Clinical Research LLC

    Binghamton, New York

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Advantage Clinical Trials

    The Bronx, New York

  • Velocity Clinical Research, Inc.

    Cleveland, Ohio

  • Allegheny Health and Wellness Pavilion

    Erie, Pennsylvania

  • Liberty Family Practice

    Erie, Pennsylvania

  • Lockman & Lubell Pediatric Associates

    Fort Washington, Pennsylvania

  • Hasbro Children's Hospital

    Providence, Rhode Island

  • Rhode Island Hospital

    Providence, Rhode Island

  • The Miriam Hospital

    Providence, Rhode Island

  • Velocity Clinical Research Providence

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.